Validations Queue
111,300 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 23 of 88, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
111,300
Reviewed
13
Filtered
4,390
page 23 / 88
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.61 | FDA ANDA219257: ANDA219257 ((unspecified)) — RENATA LIMITED | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA220046: FLUORESCEIN SODIUM (FLUORESCEIN SODIUM) — BPI LABS | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA204026: POMALYST (POMALIDOMIDE) — BRISTOL | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.61 | FDA ANDA218897: VALSARTAN (VALSARTAN) — LAURUS | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA220837: EVDI (TRABECTEDIN) — APOTEX | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA202949: DULOXETINE HYDROCHLORIDE (DULOXETINE HYDROCHLORIDE) — ALEMBIC | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA205232: PERPHENAZINE (PERPHENAZINE) — ZYDUS PHARMS | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205232: PERPHENAZINE (PERPHENAZINE) — ZYDUS PHARMS | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA213603: GABAPENTIN (GABAPENTIN) — ZHEJIANG YONGTAI | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA071199: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — BARR | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA076958: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — TEVA | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA218364: LEVETIRACETAM IN SODIUM CHLORIDE (LEVETIRACETAM) — MYLAN LABS LTD | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA077982: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — APOTEX | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA220444: PALBOCICLIB (PALBOCICLIB) — DR. REDDY'S LABORATORIES LIMITED | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA212927: TIOCYSTIN (TIOPRONIN) — CASPER PHARMA LLC | fda 2026-06-02 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.61 | FDA ANDA077132: RISEDRONATE SODIUM (RISEDRONATE SODIUM) — TEVA PHARMS USA | fda 2026-06-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA200296: RISEDRONATE SODIUM (RISEDRONATE SODIUM) — AUROBINDO PHARMA LTD | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA BLA761369: HYMPAVZI (MARSTACIMAB-HNCQ) — PFIZER INC | fda 2026-06-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA204196: DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (DEXTROMETHORPHAN HYDROBROMIDE) — SUN PHARM | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761262: SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE INC | fda 2026-06-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA208815: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — ACTAVIS LABS FL | fda 2026-06-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA206822: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — PHARM ASSOC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA209655: FENTANYL-100 (FENTANYL) — ZYDUS PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA206456: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — PHARMOBEDIENT | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA206470: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ACTAVIS LABS FL INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA220073: ELIQUIS (APIXABAN) — BRISTOL | fda 2026-06-24 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.61 | FDA ANDA204278: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — PADAGIS US | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA079087: OXYMORPHONE HYDROCHLORIDE (OXYMORPHONE HYDROCHLORIDE) — IMPAX LABS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA204640: ADRENALIN (EPINEPHRINE) — PH HEALTH | fda 2026-06-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA202426: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — APOTEX | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA NDA217369: ZURZUVAE (ZURANOLONE) — BIOGEN INC | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA218390: INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — NEUROCRINE | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA220788: SODIUM BICARBONATE (SODIUM BICARBONATE) — ASPIRO | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA078945: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — AVET LIFESCIENCES | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA077982: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — APOTEX | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA205564: LEVOCETIRIZINE DIHYDROCHLORIDE (LEVOCETIRIZINE DIHYDROCHLORIDE) — MACLEODS PHARMS LTD | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA209817: NUZYRA (OMADACYCLINE TOSYLATE) — PARATEK PHARMS | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA215820: PHYTONADIONE (PHYTONADIONE) — DR REDDYS | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA215820: PHYTONADIONE (PHYTONADIONE) — DR REDDYS | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA062801: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA070311: DIAZEPAM (DIAZEPAM) — HIKMA | fda 2026-06-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA BLA761460: DECNUPAZ (PIVEKIMAB SUNIRINE-PVZY) — ABBVIE INC | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.61 | FDA ANDA204575: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — AUROLIFE PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.61 | FDA ANDA040330: PERCOCET (ACETAMINOPHEN) — OZANTRI | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% |